Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID‐19: A phase 2a, open‐label, single‐dose escalation study
暂无分享,去创建一个
M. Vissers | G. Groeneveld | J. Burggraaf | V. Stavropoulou | I. Kamerling | Cécile L Berends | C. Zitt | M. Soergel | J. L. van der Plas | Gaby Tresch | Daniël Duijsings | E. Fernández | Manon L M Prins | Nikita van den Berge | Maya Zimmermann | Roxana F Drake
[1] M. Stumpp. Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants , 2021, bioRxiv.
[2] Janet Diaz,et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus , 2021, The Lancet Infectious Diseases.
[3] P. Pang,et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. , 2021, The New England journal of medicine.
[4] John D. Davis,et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 , 2021, The New England journal of medicine.
[5] D. Skovronsky,et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 , 2021, The New England journal of medicine.
[6] Santosh Shenoy. SARS-CoV-2 (COVID-19), viral load and clinical outcomes; lessons learned one year into the pandemic: A systematic review , 2021, World journal of critical care medicine.
[7] G. Biele,et al. Estimating infectiousness throughout SARS-CoV-2 infection course , 2021, Science.
[8] K. Neuzil. Interplay between Emerging SARS-CoV-2 Variants and Pandemic Control. , 2021, The New England journal of medicine.
[9] D. Fremont,et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies , 2021, Nature Medicine.
[10] H. Ullum,et al. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients , 2021, Scientific Reports.
[11] D. Skovronsky,et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. , 2021, JAMA.
[12] D. Broering,et al. Effect of COVID-19 on liver abnormalities: a systematic review and meta‐analysis , 2020, Scientific Reports.
[13] E. Vieira,et al. COVID-19 gastrointestinal manifestations: a systematic review , 2020, Revista da Sociedade Brasileira de Medicina Tropical.
[14] S. Kent,et al. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies , 2020, Nature Microbiology.
[15] R. Fiorotto,et al. Abnormal Liver Function Tests in Patients With COVID‐19: Relevance and Potential Pathogenesis , 2020, Hepatology.
[16] S. Lindstrom,et al. US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 , 2020, Emerging infectious diseases.
[17] Francisco J. López,et al. Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration , 2018, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[18] Arthur Christopoulos,et al. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview , 2017, British journal of pharmacology.
[19] A. Tolcher,et al. Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin , 2011, Clinical Cancer Research.
[20] Paulette Gallant,et al. Evaluation of a Visual Infusion Phlebitis Scale for Determining Appropriate Discontinuation of Peripheral Intravenous Catheters , 2006, Journal of infusion nursing : the official publication of the Infusion Nurses Society.
[21] R. Rappaport,et al. Development of an improved microneutralization assay for respiratory syncytial virus by automated plaque counting using imaging analysis , 2005, Virology Journal.
[22] G. Kärber,et al. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche , 1931, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.
[23] A. Malik,et al. Protein transport across the lung epithelial barrier. , 2003, American journal of physiology. Lung cellular and molecular physiology.
[24] C. Spearman,et al. The method of 'right and wrong cases' ('constant stimuli') without Gauss's formulae , 1908 .